C
Cezary Szczylik
Researcher at Medical University of Warsaw
Publications - 291
Citations - 30393
Cezary Szczylik is an academic researcher from Medical University of Warsaw. The author has contributed to research in topics: Renal cell carcinoma & Cancer. The author has an hindex of 49, co-authored 274 publications receiving 27380 citations. Previous affiliations of Cezary Szczylik include Military Medical Academy & Cora.
Papers
More filters
Journal ArticleDOI
Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
TL;DR: Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinIB,nilotinib, nilotinib and the potential targets for other Kinase inhibitors seem to be VEGFR and PDGFR.
Journal ArticleDOI
Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.
Raefa Abou Khouzam,Klaudia Brodaczewska,Aleksandra Filipiak,Nagwa Ahmed Zeinelabdin,Stéphanie Buart,Cezary Szczylik,Claudine Kieda,Salem Chouaib,Salem Chouaib +8 more
TL;DR: In this paper, the authors proposed a vascular normalization approach to restore the tumor vasculature to enhance tumor perfusion, relieve hypoxia, and reshaping anti-tumor immunity.
Journal ArticleDOI
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Jose Manuel Ruiz-Morales,Marcin Swierkowski,J. Connor Wells,Anna Paola Fraccon,Felice Pasini,Frede Donskov,Georg A. Bjarnason,Jae-Lyun Lee,Hao-Wen Sim,Andrzej Sliwczynsk,Aneta Ptak-Chmielewska,Zbigniew Teter,Benoit Beuselinck,Lori Wood,Takeshi Yuasa,Carmel Pezaro,Brian I. Rini,Cezary Szczylik,Toni K. Choueiri,Daniel Y.C. Heng +19 more
TL;DR: SU and PZ have similar efficacy in the first-line setting for mRCC and do not affect outcomes with subsequent second-line treatment, confirmed in real-world practice.
Journal ArticleDOI
The role of Tau protein in resistance to paclitaxel
TL;DR: Current knowledge on predictive value of protein Tau in response to taxanes is reviewed and better understanding of its role may facilitate patients selection to this sort of treatment and lead to treatment optimization.
Journal ArticleDOI
Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis.
Aleksandra Semeniuk-Wojtaś,Arkadiusz Lubas,Rafał Stec,Tomasz Syryło,Stanisław Niemczyk,Cezary Szczylik +5 more
TL;DR: Investigating the prognostic value of inflammation markers in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors demonstrates that host immune markers could be valuable predictors of clinical outcome.